CellSource Co

CellSource Co R&D Expenses

The Research & Development Expenses of CellSource Co (4880.T) as of Oct 28, 2026 is 19.07 M JPY. In the previous year, Research & Development Expenses was 71.01 M JPY — a change of -73.14% (lower).

R&D Expenses

19.07 MJPY

YoY

-73.14%

Last updated:

Research & Development Expenses of CellSource Co is 2025 19.07 M JPY. Research & Development Expenses of CellSource Co was 2024 71.01 M JPY. It decreases by -73.14% lower compared to the previous year.

The CellSource Co R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2018
6.88 M JPY
Jan 1, 2019
8.00 M JPY
Jan 1, 2020
10.82 M JPY
Jan 1, 2021
71.16 M JPY
Jan 1, 2022
87.56 M JPY
Jan 1, 2023
72.45 M JPY
Jan 1, 2024
71.01 M JPY
Jan 1, 2025
19.07 M JPY
The CellSource Co R&D Expenses history
YEARR&D ExpensesYoY
19.07 MJPY-73.14%
71.01 MJPY-1.99%
72.45 MJPY-17.26%
87.56 MJPY+23.05%
71.16 MJPY+557.86%
10.82 MJPY+35.23%
8.00 MJPY+16.26%
6.88 MJPY+68.26%
4.09 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Research & Development Expenses of CellSource Co is 19.07 M JPY in 2025.

Research & Development Expenses of CellSource Co changed from 71.01 M JPY to 19.07 M JPY, representing a -73.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses CellSource Co since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's CellSource Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — CellSource Co

All Key Metrics — CellSource Co